| Item 1.01 | Entry Into a Material Definitive Agreement |
On February 22, 2023, Apellis Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 3,174,603 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and, in lieu of Common Stock to investors who so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,380,956 shares of Common Stock (the “Warrant Shares”). All of the Shares and Pre-Funded Warrants are being sold by the Company. The price of the Shares to the public in the Offering is $63.00 per share, and the Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $60.0075 per share. The price of the Pre-Funded Warrants to the public is $62.9999 per Warrant Share, and the Underwriters have agreed to purchase the Pre-Funded Warrants from the Company pursuant to the Underwriting Agreement at a price of $60.0074 per Warrant Share. The closing of the Offering is expected to take place on or about February 27, 2023, subject to the satisfaction of customary closing conditions.
Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 833,333 shares of Common Stock (the “Additional Shares”), at the same price per share as the Shares.
The Company estimates that the net proceeds from the Offering will be approximately $333.0 million, or approximately $383.0 million if the Underwriters exercise in full their option to purchase Additional Shares, in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, along with the cash anticipated to be generated from sales of EMPAVELI and SYFOVRE and the committed development reimbursement payments from Swedish Orphan Biovitrum AB (Publ), will enable the Company to fund its operating expenses and capital expenditure requirements into the first quarter of 2025. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than currently expected.
The Shares, the Pre-Funded Warrants (including the Warrant Shares) and any Additional Shares will be issued pursuant to a prospectus supplement dated February 22, 2023 and an accompanying base prospectus that form a part of the automatically effective registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission (“SEC”) (File No. 333-269899) on February 22, 2023.
Each Pre-Funded Warrant will have an exercise price per share of Common Stock equal to $0.0001 per Warrant Share. The exercise price and the number of Warrant Shares issuable upon exercise of each Pre-Funded Warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. Each Pre-Funded Warrant will be exercisable from the date of issuance until the date the Pre-Funded Warrant is exercised in full. Under the Pre-Funded Warrants, neither the Company nor a holder may effect the exercise of any Pre-Funded Warrant, which, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates and certain related persons) to exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of the Company’s securities then immediately outstanding after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 14.99% upon 61 days’ notice to the Company.
In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded Warrants immediately prior to the fundamental transaction; provided, however, that in the event of a fundamental transaction where the consideration consists solely of cash, solely of marketable securities or a combination of cash and marketable securities, each Pre-Funded Warrant will automatically be deemed to be exercised in full in a cashless exercise effective immediately prior to and contingent upon the consummation of such fundamental transaction.
